Technical Analysis for KZIA - Kazia Therapeutics Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Earnings Movers | Other | 2.22% | |
| Inside Day | Range Contraction | 2.22% | |
| Wide Bands | Range Expansion | 2.22% | |
| Gapped Down | Weakness | 2.22% | |
| New Uptrend | Bullish | -2.82% | |
| Earnings Movers | Other | -2.82% | |
| Wide Bands | Range Expansion | -2.82% | |
| Gapped Down | Weakness | -2.82% | |
| 180 Bullish Setup | Bullish Swing Setup | 2.41% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Possible Inside Day | about 18 hours ago |
| 10 DMA Support | about 21 hours ago |
| Up 3% | about 21 hours ago |
| Up 2% | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 10/30/2024
Kazia Therapeutics Limited Description
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Cancer Treatment ATM Chemotherapy Ovarian Cancer Blastoma Cancer Cell Glioma Neuroblastoma Cytoskeleton Diffuse Intrinsic Pontine Glioma Novogen Pharmaceutical Research
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.8 |
| 52 Week Low | 1.866 |
| Average Volume | 150,998 |
| 200-Day Moving Average | 3.47 |
| 50-Day Moving Average | 4.16 |
| 20-Day Moving Average | 4.78 |
| 10-Day Moving Average | 5.42 |
| Average True Range | 0.58 |
| RSI (14) | 59.18 |
| ADX | 26.78 |
| +DI | 24.78 |
| -DI | 18.40 |
| Chandelier Exit (Long, 3 ATRs) | 4.74 |
| Chandelier Exit (Short, 3 ATRs) | 5.01 |
| Upper Bollinger Bands | 6.37 |
| Lower Bollinger Band | 3.19 |
| Percent B (%b) | 0.73 |
| BandWidth | 66.56 |
| MACD Line | 0.41 |
| MACD Signal Line | 0.37 |
| MACD Histogram | 0.0419 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.06 | ||||
| Resistance 3 (R3) | 6.08 | 5.92 | 5.97 | ||
| Resistance 2 (R2) | 5.92 | 5.78 | 5.91 | 5.94 | |
| Resistance 1 (R1) | 5.72 | 5.70 | 5.82 | 5.70 | 5.91 |
| Pivot Point | 5.56 | 5.56 | 5.61 | 5.55 | 5.56 |
| Support 1 (S1) | 5.36 | 5.42 | 5.46 | 5.34 | 5.13 |
| Support 2 (S2) | 5.20 | 5.34 | 5.19 | 5.10 | |
| Support 3 (S3) | 5.00 | 5.20 | 5.07 | ||
| Support 4 (S4) | 4.98 |
